

## **PRESS RELEASE**

### **DORNIER MEDTECH COLLABORATOR AWARDED BEST POSTER PRIZE FOR POSTER ON LOW INTENSITY SHOCKWAVE AND ERECTILE DYSFUNCTION**

- *Landmark study indicates for the first time that LiST can be safely administered via Dornier's ARIES 2 up to three times a week for the treatment of ED*

**Singapore, 15 October 2018** – Dornier MedTech (Dornier), a global leader in urology and wholly owned subsidiary of Accuron MedTech Group (Accuron MedTech), today announced that its collaborating research team was awarded the best poster presentation prize at the 13th South Eastern European Meeting for a poster on the results of a clinical trial using Dornier MedTech's Dornier Aries 2 device.

The prize-winning poster presentation entitled *“Low-intensity shockwave therapy (LiST) for erectile dysfunction: A randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions”* detailed a randomized clinical trial investigating the safety and efficacy of two different session frequencies per week and two different energy levels. The trial was conducted by a research team, led by Dornier MedTech collaborator and world-renowned urologist Professor Dimitris Hatzichristou.

96 patients were divided into 4 groups: A, B, C and D. Patients in Group A received LiST at EFD 0.05mJ/mm<sup>2</sup> for two sessions per week, while patients in Group B received LiST at EFD 0.05mJ/mm<sup>2</sup> for three sessions per week. Patients in Group C received LiST at EFD 0.10mJ/mm<sup>2</sup> for two sessions per week, while patients in Group D received LiST at EFD 0.10mJ/mm<sup>2</sup> for three sessions per week. Each patient received a total of 12 sessions of LiST treatment. Patients in Groups A and C took 6 weeks to complete 12 sessions, while patients in Groups B and D took 4 weeks to complete 12 sessions. Patients were followed up at 1- and 3-months post-treatment.

All patients in the study showed improvement in erectile function even after only one month post-treatment, without any adverse effects. This landmark study indicates for the first time that LiST can be safely administered on patients up to three times a week. The study also showed that LiST with EFD 0.10mJ/mm<sup>2</sup> is slightly more

[www.dornier.com](http://www.dornier.com)

**Address:** 2 Venture Drive, #23-18 Vision Exchange, Singapore 608526

**Telephone:** +65-6572-6068 **Fax:** +65-6572-6093 **Email:** infoasia@dornier.com

effective than LiST with EFD 0.05mJ/mm<sup>2</sup>. Reviewed together, Professor Dimitris Hatzichristou and his team suggested implementing two to three sessions per week of LiST at EFD 0.10mJ/mm<sup>2</sup> for a total of 12 sessions and this is immediately applicable to clinical practice.

**Wong Yau Chung, Head, Dornier ARIES Group** said: “As a global market leader in erectile dysfunction treatment, we are proud of the team’s recognition by a leading urology association for the quality of clinical studies they are conducting in the growing field for ESWT for erectile dysfunction. Doctors using the new protocol with Dornier ARIES 2 for vasculogenic ED are already reporting better outcomes for patients, confirming the applicability of the study results in clinical practice and their importance in ensuring we offer the best treatment solutions for patients.”

The poster has been selected to be presented at the 34th Annual EAU Congress in Barcelona in March 2019.

This study, together with the study published in March this year comparing the efficacy and safety of 6, 12, 18 treatment sessions<sup>1</sup>, is an example of Dornier MedTech’s continuous strive to achieve the best experience and treatment outcomes for our end-users<sup>1</sup>.

## Ends

### Media Contact:

**Emma Thompson /Tianning He /Clarinda Ng**  
Spurwing Communications  
+65 6340 7287  
[accuron@spurwingcomms.com](mailto:accuron@spurwingcomms.com)

### About Dornier MedTech

---

<sup>1</sup> Kalyvianakis D, Memmos E, Mykoniatis I, Kapoteli P, Memmos D, Hatzichristou D. *Low-Intensity Shockwave Therapy for Erectile Dysfunction: A Randomized Clinical Trial Comparing 2 Treatment Protocols and the Impact of Repeating Treatment*. J Sex Med. 2018 Mar;15(3):334-345.



Dornier MedTech is headquartered in Munich, Germany, and is a full subsidiary of Accuron MedTech. Dornier is a medical device company focused on providing leading technology and improving life by delivering scientifically superior products and solutions to physicians, healthcare providers and research groups involved in urological care. As pioneers of the lithotripsy and a variety of surgical lasers, Dornier's 40 years of innovation and service have made it one of the most trusted MedTech companies in the industry.

**About Accuron MedTech Group**

Accuron MedTech Group is one of the largest medical device companies in Southeast Asia. It is a vertically integrated medical device company and a global medical technology leader with a core focus in urology devices and services. Headquartered in Singapore, with operations in US, Germany, Spain, France, Italy, China, Malaysia and Japan, the Company serves millions of patients and physicians in about 100 countries worldwide. Accuron MedTech makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world. Accuron MedTech is an independent division of Accuron Technologies, a wholly-owned subsidiary of Temasek Holdings. For more information on Accuron MedTech, please visit [www.accuronmedtech.com](http://www.accuronmedtech.com).

[www.dornier.com](http://www.dornier.com)

**Address:** 2 Venture Drive, #23-18 Vision Exchange, Singapore 608526

**Telephone:** +65-6572-6068 **Fax:** +65-6572-6093 **Email:** infoasia@dornier.com